Article info

PDF

Original article
Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1

Authors

  1. Correspondence to Catherine L Shuler; shuler_catherine_l{at}lilly.com
View Full Text

Citation

Coates LC, Kishimoto M, Gottlieb A, et al
Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1

Publication history

  • Received August 25, 2017
  • Revision received October 16, 2017
  • Accepted November 5, 2017
  • First published December 22, 2017.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.